AEMD

Aethlon Medical, Inc. (AEMD) Shareholder/Analyst Call Prepared Remarks Transcript

NEW YORK, Sept. 18, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC  (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report.

BALA CYNWYD, Pa., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.

North Immunology's lead program, NOR-101, is a half-life extended anti-IL-13 x IL-18 bispecific antibody designed to inhibit both type 2 and non-type 2 inflammation, with the potential to deliver a best-in-disease treatment for patients with atopic dermatitis Oversubscribed $180 million private placement is expected to fund the combined company's operations into the second half of 2028 Phase 1a study of NOR-101 is expected to begin in the first quarter of 2027, with interim pharmacokinetic and safety data expected by mid-2027 and Phase 1b and Phase 2b topline data expected in 2028 SAN DIEGO and AUSTIN, Texas, Sept. 17, 2026 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD) ("Aethlon" or the "Company") today announced that it has entered into a definitive merger agreement (the "Agreement") for an all-stock transaction with North Immunology, Inc. ("North Immunology"), Nighthawk Merger Sub Corp., a wholly owned subsidiary of Aethlon, and Nighthawk Second Merger Sub, LLC, a wholly owned subsidiary of Aethlon.

Conference Call Today at 4:30 p.m. ET SAN DIEGO, Aug. 13, 2026 /PRNewswire/ -- Aethlon Medical, Inc. (the Company or Aethlon) (Nasdaq: AEMD), a clinical-stage medical therapeutic company, today announced financial results for fiscal first quarter ended June 30, 2026, and provided a corporate update.

SAN DIEGO, Aug. 5, 2026 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases, today announced that it will issue financial results for its fiscal first quarter ended June 30, 2026, at 4:15 p.m. ET on Thursday, August 13, 2026.

Second cohort findings consistent with previously reported observations; independent statistical analysis planned following completion of all three patient cohorts SAN DIEGO, July 13, 2026 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company developing products to treat cancer and life-threatening viral infections, today announced that patients in the second cohort of its Australian oncology feasibility study demonstrated biological changes consistent with those previously observed in the first cohort following treatment with the investigational Hemopurifier®. Replicating these findings in a second group of patients strengthens the scientific rationale for the Company's ongoing clinical program and supports continued enrollment in the third and final cohort before an independent statistical analysis is conducted.

SAN DIEGO, July 6, 2026 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced the pricing of its follow-on offering of 5,633,009 shares of its common stock (or pre-funded warrants in lieu thereof) and warrants to purchase up to an aggregate of 5,633,009 shares of its common stock at a combined public offering price of $0.7101 per share (or pre-funded warrant) and accompanying warrant, priced at-the-market under applicable Nasdaq rules. The warrants will have an exercise price of $0.7101 per share, will be exercisable upon the date of stockholder approval, and will expire on the five-year anniversary from the date of stockholder approval.

Peer-reviewed study identifies altered extracellular vesicles in Long COVID and provides additional scientific rationale for evaluating the Hemopurifier® as a potential treatment SAN DIEGO, June 26, 2026 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced publication of new peer-reviewed research in the International Journal of Molecular Sciences demonstrating that patients with Long COVID exhibit significantly increased levels of mannosylated extracellular vesicles (EVs) that can be captured using the same Galanthus nivalis agglutinin (GNA) affinity resin incorporated into the Company's Hemopurifier®. The study, conducted in collaboration with investigators from the University of California, San Francisco (UCSF), provides what we believe is new evidence supporting extracellular vesicles as a potential therapeutic target in Long COVID and helps establish a translational framework for future studies evaluating whether the Hemopurifier can remove disease-associated EVs and their molecular cargo.

Aethlon Medical, Inc. (AEMD) Q4 2026 Earnings Call Transcript